BIOKIN PHARMACEUTICAL(SH:688506) Xin Hua She·2025-09-19 08:42Core Insights - The 2025 World Lung Cancer Conference showcased significant advancements in innovative drugs from Chinese pharmaceutical companies, highlighting the increasing international recognition of Chinese innovation in the pharmaceutical sector [1] Group 1: Conference Highlights - The conference featured 35 oral presentations from Chinese scholars, with two participating in the chair discussion, indicating a strong presence of Chinese research [1] - Baili Tianheng's drug, iza-bren, is the world's first and only EGFR×HER3 dual antibody ADC to enter Phase III clinical trials, with two key research results selected for the conference's official news release program [1][3] Group 2: Clinical Research Results - In a Phase II study, 40 patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC) treated with iza-bren and osimertinib showed effective tumor shrinkage, outperforming the current best drug's 86% shrinkage rate [2] - Another study reported that 94% of 50 patients with advanced EGFR-mutant NSCLC experienced tumor shrinkage, with a time to recurrence exceeding one year, nearly doubling the duration compared to existing global standards [2] Group 3: ADC Development and Market Trends - ADCs are recognized as a highly innovative and promising direction in cancer treatment, with over 120 Chinese pharmaceutical companies engaged in ADC research and more than 600 projects globally [2] - From 2018 to 2024, China has approved a total of 197 innovative drugs, with the annual approval rate increasing from 11 in 2018 to 48 in 2024, indicating a robust growth trend in innovative drug development [3] Group 4: Strategic Partnerships and Market Positioning - Baili Tianheng entered a global strategic partnership with Bristol-Myers Squibb for iza-bren, with a total deal value of up to $8.4 billion, marking a significant milestone for a Chinese dual antibody ADC [4] - The company's market capitalization surged from 9.9 billion yuan at its IPO to over 150 billion yuan, reflecting strong investor interest and confidence in its innovative drug pipeline [4] Group 5: Future Plans and Industry Advantages - Baili Tianheng plans to commercialize its innovative drugs in China by 2026 and aims for global market approval by 2029, aspiring to become a competitive multinational corporation (MNC) [5] - The company leverages China's unique advantages, including a growing number of biotech firms, robust clinical research infrastructure, and an efficient regulatory environment, to enhance its drug development capabilities [6]